PCSK9
Proprotein convertase subtilisin/kexin type 9
The protein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene located on human chromosome 1. It is the ninth member of the protein convertase family, a group of enzymes that can activate homologous genes found in many species[1]. PCSK9 is a liver-synthesized protease that plays a major role in regulating the levels of low-density lipoprotein receptors (LDLR) on the surface of liver cells and can inhibit the LDLR recycling pathway. PCSK9 binds to LDLR on the surface of liver cells, escorts LDLR to lysosomes for degradation, and prevents LDLR from recirculating to the cell membrane, effectively increasing the level of circulating LDL. Therefore, inhibiting the activity of the PCSK9 protease can down-regulate circulating LDL levels. PCSK9 is closely associated with various cardiovascular diseases, especially hypercholesterolemia and atherosclerosis[2].
All Product Categories
-
PCSK9 Related Products (109)
Related Products (109)
-
Levofloxacin
0 ImagesSynonyms: (-)-OfloxacinLevofloxacin ((-)-Ofloxacin) is an orally active broad-spectrum antibacterial agent with antioxidant and antibacterial activities. Levofloxacin upregulates TC synthesis-related genes and transport-related genes, reduces plasma PCSK9, inhibits GABAA receptors and mitochondrial complexes I/III, scavenges hydroxyl radicals and neutrophil-derived ROS, and inhibits NO metabolites and interferon-γ. Levofloxacin improves survival, alleviates lung injury, and reduces oxidative and inflammatory markers in influenza virus-infected mice. Levofloxacin inhibits lung cancer proliferation and xenograft tumor growth, and induces apoptosis and oxidative stress. Levofloxacin can be used in research on bacterial infection, influenza virus infection, atherosclerosis, and lung cancer.
-
Bococizumab
0 ImagesSynonyms: PF-04950615; RN316Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.
-
Inclisiran sodium
0 ImagesCat. No.: HY-132591APurity: 99.08%Synonyms: ALN-PCSsc sodiumInclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD).
-
Inclisiran
0 ImagesSynonyms: ALN-PCSscInclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD).
-
Laroprovstat
0 ImagesSynonyms: AZD0780; PCSK9-IN-12Laroprovstat (AZD0780) is an orall active PCSK9 inhibitor. PCSK9-IN-12 has bind affinity for PCSK9 with a Kd value of <200 nM. Laroprovstat binds to a pocket in the PCSK9 C-terminal domain and does not affect the PCSK9-LDL receptor (LDLR) interaction. Laroprovstat inhibits lysosomal trafficking of PSCK9-LDLR complexes and prevents PCSK9-induced LDLR degradation. Laroprovstat can be used for the research of hypercholesterolemia.
-
Alirocumab
0 ImagesCat. No.: HY-P9928CAS No.: 1245916-14-6Synonyms: REGN727; SAR 236553Alirocumab (REGN727) is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.
-
Levofloxacin hydrate
0 ImagesSynonyms: Levofloxacin hemihydrateLevofloxacin hydrate (Levofloxacin hemiHYdrate) is an orally active broad-spectrum antibacterial agent with antioxidant and antibacterial activities. Levofloxacin hydrate upregulates TC synthesis-related genes and transport-related genes, reduces plasma PCSK9, inhibits GABAA receptors and mitochondrial complexes I/III, scavenges hydroxyl radicals and neutrophil-derived ROS, and inhibits NO metabolites and interferon-γ. Levofloxacin hydrate improves survival, alleviates lung injury, and reduces oxidative and inflammatory markers in influenza virus-infected mice. Levofloxacin hydrate inhibits lung cancer proliferation and xenograft tumor growth, and induces apoptosis and oxidative stress. Levofloxacin hydrate can be used in research on bacterial infection, influenza virus infection, atherosclerosis, and lung cancer.
-
Enlicitide chloride
0 ImagesSynonyms: MK-0616 chlorideEnlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders.
-
SS-Inclisiran sodium
0 ImagesCat. No.: HY-143219SS-Inclisiran sodium is a sense strand of Inclisiran (HY-132591).
-
Alirocumab (anti-PCSK9)
0 ImagesSynonyms: REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation.
-
SPC5001 sodium
0 ImagesCat. No.: HY-148687APurity: 98.89%SPC5001 sodium is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 sodium can be used for the research of hypercholesterolemia. SPC5001 sodium sequence: 5′-TGmCTACAAAACmCmCA-3′.
-
Levofloxacin hydrochloride
0 ImagesSynonyms: (-)-Ofloxacin hydrochlorideLevofloxacin hydrochloride ((-)-Ofloxacin hydrochloride) is an orally active broad-spectrum antibacterial agent with antioxidant and antibacterial activities. Levofloxacin hydrochloride upregulates TC synthesis-related genes and transport-related genes, reduces plasma PCSK9, inhibits GABAA receptors and mitochondrial complexes I/III, scavenges hydroxyl radicals and neutrophil-derived ROS, and inhibits NO metabolites and interferon-γ. Levofloxacin hydrochloride improves survival, alleviates lung injury, and reduces oxidative and inflammatory markers in influenza virus-infected mice. Levofloxacin hydrochloride inhibits lung cancer proliferation and xenograft tumor growth, and induces apoptosis and oxidative stress. Levofloxacin hydrochloride can be used in research on bacterial infection, influenza virus infection, atherosclerosis, and lung cancer.
-
SS(no Galnac)-Inclisiran sodium
0 ImagesCat. No.: HY-143220Purity: 98.05%SS (no Galnac)-Inclisiran sodium is the sense strand of Inclisiran (HY-132591) without GalNAc modification. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. SS (no Galnac)-Inclisiran sodium can be used in cardiovascular disease research.
-
Levofloxacin (Standard)
0 ImagesSynonyms: (-)-Ofloxacin (Standard)Levofloxacin (Standard) ((-)-Ofloxacin (Standard)) is the analytical standard of Levofloxacin (HY-B0330). This product is intended for research and analytical applications. Levofloxacin ((-)-Ofloxacin) is an orally active broad-spectrum antibacterial agent with antioxidant and antibacterial activities. Levofloxacin upregulates TC synthesis-related genes and transport-related genes, reduces plasma PCSK9, inhibits GABAA receptors and mitochondrial complexes I/III, scavenges hydroxyl radicals and neutrophil-derived ROS, and inhibits NO metabolites and interferon-γ. Levofloxacin improves survival, alleviates lung injury, and reduces oxidative and inflammatory markers in influenza virus-infected mice. Levofloxacin inhibits lung cancer proliferation and xenograft tumor growth, and induces apoptosis and oxidative stress. Levofloxacin can be used in research on bacterial infection, influenza virus infection, atherosclerosis, and lung cancer.
-
Anacetrapib
0 ImagesSynonyms: MK-0859
-
GalNAc unconjugated/naked Inclisiran
0 ImagesCat. No.: HY-150223Purity: 98.83%GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic PCSK9 production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia.
